| WARF: P99011US |  |
| 2-Alkyl-19-Nor-Vitamin D Compounds |
| INVENTORS | • | Hector DeLuca, Rafal Sicinski |
The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing novel vitamin D analogs that may be useful in the treatment of various diseases.
OVERVIEW
2-carbon-modified-19-nor vitamin D compounds are a novel class of vitamin D compounds that are substituted at the carbon 2 (C-2) position.
THE INVENTION
UW-Madison researchers have developed novel vitamin D analogs that exhibit a highly advantageous pattern of biological activity characterized by an intestinal calcium transport activity equal to that of 1,25-(OH)2D3 and an increased ability to mobilize calcium from bone. These 2-substituted compounds, especially the 2 alpha-methyl and the 2 alpha-methyl-20S derivatives, are highly specific in their calcemic activity. Their preferential activity on bone osteoblasts suggests these compounds may be useful in the treatment of metabolic bone diseases where bone loss is a major concern. Also, the compounds can arrest the proliferation of undifferentiated cells and induce their differentiation. This property may prove useful in the treatment of diseases such as skin disorders and certain malignancies.
APPLICATIONS
- Treatment of bone diseases, cancer and psoriasis
KEY BENEFITS
- Highly specific calcemic activity
ADDITIONAL INFORMATION
For More Information About the Inventors
Related Technologies
Intellectual Property Status
Tech Fields
Pharmaceuticals & Vitamin D - Vitamin D
CONTACT INFORMATION
For current licensing status, please contact our team at
licensing@warf.org
or phone 608.262.4924. (Clicking this link will open a contact form in a popup window. If you have problems viewing the form, try disabling your popup blocker software.)
WARF: A Leader in Technology Transfer Since 1925
Since its founding as the patenting and licensing arm of the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.
The University of Wisconsin and WARF -
A Single Location to Accelerate Translational Development of New Drugs
The UW-Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities in the country, UW-Madison offers state-of-the-art facilities unmatched by most public universities.
These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW-Madison with a complete translational research facility; and soon, the Wisconsin Institutes for Discovery, made up of innovative private and public interdisciplinary biomedical research institutes. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.
Since its founding as the patenting and licensing arm of the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.
The University of Wisconsin and WARF -
A Single Location to Accelerate Translational Development of New Drugs
The UW-Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities in the country, UW-Madison offers state-of-the-art facilities unmatched by most public universities.
These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW-Madison with a complete translational research facility; and soon, the Wisconsin Institutes for Discovery, made up of innovative private and public interdisciplinary biomedical research institutes. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.
